Novo-Nordisk - Insulinpräparate
Seite 1 von 83
neuester Beitrag: 09.04.20 14:31
|eröffnet am:||20.01.10 10:39 von:||elNacho||Anzahl Beiträge:||2067|
|neuester Beitrag:||09.04.20 14:31 von:||moggemeis||Leser gesamt:||681850|
|bewertet mit 11 Sternen
elNacho : Novo-Nordisk - Insulinpräparate
Das Geschäft mit Insulinpräparaten ist von der Wirtschafts- und Finanzkrise kaum betroffen.
Aktuell sind weltweit 250 Mio. Menschen an Diabetes erkrankt.
Mit Blick auf die Lebensweise in den Industrieländern dürfte deren Zahl künftig noch zunehmen. Für die Dänen heißt dies: Das Wachstum ist gut planbar Hoepage: http://www.novonordisk.com/
- A world lead within diabetes and haemostasis management
- Sales totalled DKK 45.6 billion in 2008 (Eur 6.1 billion)
- In 2008 total insulin market of 52% and modern insulin market share 44%, measured by volume (Source IMS)
- Some 26,500 Full time employees
- Focus on core areas with large unmet medical needs: Diabetes care, haemostasis, growth hormone disorders and other biopharmaceuticals
- Strong global marketing network
- Listed on NASDAQ OMX Copenhagen, London and New York Exchanges
elNacho : Novo Nordisk-Aktie kämpft sich frei
Die Chancen, dass der technische Ausbruch nicht nur ein Intermezzo ist, stehen gut. Denn der im August gestartete Aufwärtstrend wirkt gefestigt: Im Bereich Autoimmunerkrankungen wurde kürzlich eine Forschungskooperation begründet, im Hauptgeschäftsfeld Diabetes startete eine Phase-1-Studie für ein orales Insulin, und für das humane GLP-1-Analogon Liraglutide (Victoza®) erwartet der dänische Healthcare-Konzern "innerhalb von Wochen" Feedback von der FDA.
Die Aktie ist mit einem Kurs-Gewinn-Verhältnis von 17 (auf Basis von 2010) zwar kein Schnäppchen mehr, doch überzeugen das solide Wachstum bei Erlösen und Gewinnen sowie die hohen Nettogewinnmargen von zuletzt 22,2 Prozent.
Quelle: http://www.aerztezeitung.de/praxis_wirtschaft/...ie-kaempft-frei.html vom 18.01.2010
elNacho : Novo Nordisk über sich selbst
elNacho : JPMorgan belässt Novo Nordisk auf 'Neutral'
© 2010 APA-dpa-AFX-Analyser
elNacho : EU Kommission genehmigt Kauf von Archimedes Pharma
EU OKs Warburg Pincus, Novo Nordisk To Buy Archimedes Pharma
Bookmark and Share
1-25-10 5:35 AM EST | E-mail Article
BRUSSELS -(Dow Jones)- The European Commission Monday cleared private equity firm Warburg Pincus and Denmark's Novo Nordisk Foundation to acquire control of Archimedes Pharma Ltd.
Archimedes Pharma is a U.K.-based pharmaceutical group focused on hospitals, with products for oncology, pain, neurology and critical care, the commission said.
-By Alessandro Torello, Dow Jones Newswires; +32 2 741 14 88; email@example.com
(END) Dow Jones Newswires
Copyright (c) 2010 Dow Jones & Company, Inc.
elNacho : und es geht weiter
PRINCETON, N.J., Jan. 25 /PRNewswire/ -- Novo Nordisk , a global healthcare company, announced today the U.S. Food and Drug Administration (FDA) approved the new drug application for Victoza® (liraglutide [rDNA origin] injection), the first once-daily human glucagon-like peptide-1 (GLP-1) analog for the treatment of type 2 diabetes. Victoza is indicated as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus.
Victoza was evaluated in The Liraglutide Effect and Action in Diabetes (LEAD) phase III trials, the most comprehensive clinical development program conducted to date by Novo Nordisk in type 2 diabetes. In clinical studies including use as monotherapy and in combination with standard diabetes treatments, Victoza produced significant reductions in A1C and also was associated with weight loss.
"Novo Nordisk is committed to developing safe and effective drugs to treat diabetes, which is why the FDA approval of Victoza represents such an important milestone for the company and for people with type 2 diabetes," says Alan C. Moses, M.D., vice president, and chief global medical officer of Novo Nordisk. "Victoza will be a substantial addition to our diabetes portfolio and we believe many people with type 2 diabetes will benefit from this treatment."
"Maintaining control of blood sugar remains a challenge for many type 2 diabetes patients and without control, patients are at risk of developing serious and life-threatening complications, " said Alan J. Garber, MD, PhD, FACE, Professor of Medicine, Biochemistry and Molecular Biology, and Cellular Biology Department of Medicine Baylor College of Medicine Houston, Texas. "The approval of Victoza provides patients a once daily treatment that not only lowers blood sugar, but unlike many other diabetes therapies, does not promote weight gain and is associated with weight loss in the majority of patients. Additionally, it offers patients an attractive new treatment option that has consistently performed well when compared to other currently available treatments."
The American Diabetes Association and European Association for the Study of Diabetes as well as the American Association of Clinical Endocrinologists and the American College of Endocrinology recently updated their treatment algorithms for type 2 diabetes. The algorithms recommend GLP-1 agonists like Victoza as a viable treatment option when blood sugar goals are not met or maintained with lifestyle adjustments and metformin.
Novo Nordisk expects to introduce Victoza in the U.S. market in 4 - 6 weeks. In addition to the U.S. approval, Victoza has been approved by the European Medicines Agency (EMEA) in all 27 European Union member states, Mexico and Iceland. On January 20th, Victoza was also approved in Japan. A New Drug Application was submitted for China in August 2009, regulatory decision is pending.
Indications and Usage
Victoza is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Victoza is not recommended as first-line therapy for patients who have inadequate glycemic control on diet and exercise. It has not been studied sufficiently in patients with a history of pancreatitis. Victoza should not be used to treat type 1 diabetes mellitus or diabetic ketoacidosis. It has not been studied in combination with insulin.
Victoza is the first and only human GLP-1 analog with 97% homology to natural GLP-1. Like natural GLP-1, Victoza works by stimulating the beta cells to release insulin only when blood glucose levels are high. Due to this glucose-dependent mechanism of action, Victoza is associated with a low rate of hypoglycemia. The mechanism of blood glucose lowering also involves a delay in gastric emptying.
In clinical studies submitted for FDA review, Victoza's® safety and efficacy were evaluated in five trials, one of 52-weeks duration and four of 26-weeks duration. These multinational trials evaluated Victoza in monotherapy as well as in combination with one or two oral anti-diabetic medications and showed better lowering of blood glucose than active comparators such as sulfonylureas and thiazolidinediones. A1C reductions for Victoza 1.8 mg, in combination or as monotherapy, ranged from 1.0% to 1.5% across the five clinical studies with baselines ranging from 8.2% to 8.6%. Victoza 1.8 mg + metformin reduced A1C by 1.0% and reduced weight by 6.2lbs. The most common adverse reactions reported in patients treated with Victoza are headache, nausea, diarrhea, and anti-liraglutide antibody formation. Immunogenicity-related events, including urticaria, were more common among Victoza-treated patients than among comparator-treated patients in clinical trials.
For full prescribing information, please go to Victoza.com or call 1-877-4VICTOZA (484-2869).
On January 26, 2010 at 08:00 am CET, corresponding to 02:00 am EST, a conference call for investors will be held. Investors will be able to listen in via a link on the investor section of novonordisk.com. Presentation material for the conference call will be made available approximately one hour before on the same page, and a replay of the conference call will be available approximately two hours after its conclusion.
Important Safety Information
Victoza causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether Victoza causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as human relevance could not be ruled out by clinical or nonclinical studies. Victoza is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Based on the findings in rodents, monitoring with serum calcitonin or thyroid ultrasound was performed during clinical trials, but this may have increased the number of unnecessary thyroid surgeries. It is unknown whether monitoring with serum calcitonin or thyroid ultrasound will mitigate human risk of thyroid C-cell tumors. Patients should be counseled regarding the risk and symptoms of thyroid tumors.
In clinical trials, there were more cases of pancreatitis among Victoza-treated patients than among comparator-treated patients. If pancreatitis is suspected, Victoza should be discontinued. Victoza should not be re-initiated if pancreatitis is confirmed. Use with caution in patients with a history of pancreatitis.
When Victoza is used with an insulin secretagogue (e.g. a sulfonylurea) serious hypoglycemia can occur. Consider lowering the dose of the insulin secretagogue to reduce the risk of hypoglycemia.
There have been no studies establishing conclusive evidence of macrovascular risk reduction with Victoza or any other antidiabetic drug.
The most common adverse reactions reported in patients treated with Victoza are headache, nausea, diarrhea, and anti-liraglutide antibody formation. Immunogenicity-related events, including urticaria, were more common among Victoza-treated patients than among comparator-treated patients in clinical trials.
Victoza has not been studied in type 2 diabetes patients below 18 years of age and is not recommended for use in pediatric patients.
Victoza should be used with caution in patients with renal impairment and in patients with hepatic impairment.
About Type 2 Diabetes
Approximately 220 million people worldwide have diabetes, the vast majority of which is type 2 which is caused by a combination of insulin resistance and inadequate and progressive dysfunction of the cells (beta cells) that produce and release insulin. In fact, studies show that 50% of beta-cell function is lost by the time of diagnosis. In the U.S. alone, approximately 24 million people have type 2 diabetes. Despite the availability of many treatments, close to 45% of people with type 2 diabetes are not achieving A1C goals. Lack of glycemic control puts patients at serious risk; for every 1% increase in A1C above 6%, the risk of death increases by 20%.
Further complicating the disease, 85% of people with type 2 diabetes are overweight or obese, and obesity increases insulin resistance, cardiovascular risk, and mortality. People with type 2 diabetes are at high risk of cardiovascular disease and have higher morbidity and mortality when cardiovascular events occur.
As the burden of type 2 diabetes continues to grow, innovation in developing drugs and improving health care delivery is needed if the epidemic and its consequences are expected to be stopped or reversed.
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 29,000 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.
CONTACT: Media: Elin K. Hansen, +45-4442-3450, firstname.lastname@example.org; or
Investors: Klaus Bulow Davidsen, +45-4442-3716, email@example.com; or
Kasper Roseeuw Poulsen, +45-4442-4471, firstname.lastname@example.org; Hans Rommer,
+1-609-919-7937; email@example.com; or In North America: An Phan,
Web Site: http://www.novonordisk.com/
elNacho : und die deutsche Zusammenfassung dazu
Kopenhagen (BoerseGo.de) - Der dänische Diabetesspezialist Novo Nordisk hat von der US-Gesundheitsbehörde FDA die Zulassung für das Medikament Victoza erhalten. Victoza sei zur Behandlung von Diabetes mellitus Typ 2 bei Erwachsenen zugelassen worden, teilte das Unternehmen am Dienstag mit. Victoza darf den Angaben zufolge sowohl zur Einzelanwendung als auch in Kombination mit anderen Medikamenten verschrieben werden. Die Markteinführung in den USA soll in den kommenden Wochen erfolgen. In Europa und Japan ist das Medikament ebenfalls bereits zugelassen.
(© BörseGo AG 2007 - http://www.boerse-go.de, Autor: Baron Oliver, Redakteur)
© 2010 BörseGo
elNacho : Novo Nordisk: Final Results
Novo Nordisk increased operating profit by 21% in 2009
In 2010, operating profit is expected to increase by around 10%
-- Sales increased by 12% in Danish kroner and by 11% in local currencies.
*Sales of modern insulins increased by 24%
(23% in local currencies).
*Sales of NovoSeven® increased by 11%
(10% in local currencies).
*Sales of Norditropin® increased by 14%
(10% in local currencies).
*Sales in North America increased by 21%
(15% in local currencies).
*Sales in International Operations increased by 17%
(19% in local currencies).
-- Gross margin improved by 1.8 percentage points to 79.6% in 2009,
primarily reflecting continued productivity improvements, price
increases in the US and a positive currency impact of around 0.4
-- Reported operating profit increased by 21% to DKK 14,933 million.
Adjusted for the impact from currencies underlying operating profit
increased by more than 15%.
-- Net profit increased by 12% to DKK 10,768 million. Earnings per share
(diluted) increased by 15% to DKK 17.82.
-- At the Annual General Meeting on 24 March 2010, the Board of Directors
will propose a 25% increase in dividend to DKK 7.50 per share of DKK 1.
The Board of Directors has furthermore decided to initiate a new share
repurchase programme of DKK 7.5 billion during 2010.
-- In January 2010, Novo Nordisk received marketing authorisation for
Victoza®, the once-daily human GLP-1 analogue for the treatment of
type 2 diabetes, from both the US Food and Drug Administration (FDA)
and the Japanese Ministry of Health, Labour and Welfare.
-- For 2010, sales growth measured in local currencies is expected to be
in the range of 6-10% whereas operating profit measured in local
currencies is expected to increase by around 10%.
Lars Rebien Sørensen, president and CEO, said: "We are satisfied with the solid business performance in 2009, which is primarily driven by the robust sales growth for our portfolio of modern insulins. The launch of Victoza® in Europe is very encouraging and we look forward to continuing the global roll-out of Victoza® following the recent approvals in the US and Japan."
Further information about Novo Nordisk is available on the company's homepage http://novonordisk.com/
Company Announcement no 4 2010 : http://hugin.info/2013/R/1379438/339497.pdf
elNacho : Novo Nordisk wächst kräftig
Der Vorstand wird der Hauptversammlung am 24. März 2010 die Anhebung der Dividende um 25 Prozent auf 7,50 DKK pro Aktie vorschlagen. Zudem kündigte das Unternehmen ein neues Aktienrückkaufprogramm für 2010 im Volumen von 7,5 Milliarden DKK an.
Für das laufende Jahr rechnet das Unternehmen mit einem Umsatzanstieg um 6 bis 10 Prozent und einem Anstieg des operativen Gewinns um 10 Prozent, jeweils gemessen in lokalen Währungen.
(© BörseGo AG 2007 - http://www.boerse-go.de, Autor: Baron Oliver, Redakteur)
© 2010 BörseGo
elNacho : Citigroup hebt Ziel für Novo Nordisk auf 360 Krone
© 2010 APA-dpa-AFX-Analyser
Havakuk : 600% plus! Sind so lange Dochte echt?
Der Jahres-Chart von Novo-Nordisk (L&S RT) sieht als als Mountain gut aus, und ich habe heute 100 zu 50 gekauft.
Als Candlestik (L&S RT) wirkt er extrem flach, weil da 4 Dochte bis über 300 ? ragen. Wie kommt das denn?
Wenn es wirklich Dummis gibt, die in einem engen Markt "billigst" ordern und dann so einen Preis zahlen,
dann kann ich doch gleich mal eine Verkaufsorder über 200 ? erteilen und geduldig auf´s nächste Dummi warten.
Oder sind solche Charts fehlerhaft? - Wenn niemand antwortet muß ich wohl bei Lange und Schwarz anfragen.
Oder vielleicht antwortet freundlicherweise ein börsenerfahrener Moderator?
elNacho : Rückkauf programm läuft
Novo Nordisk A/S - Share repurchase programme
On 2 February 2010 Novo Nordisk initiated its share repurchase programme in
accordance with the provisions of the European Commission's regulation no
2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.
Under the programme Novo Nordisk will repurchase B shares for an amount up to
DKK 2.0 billion in the period from 2 February 2010 to 26 April 2010.
Since the announcement as of 8 February 2010, the following transactions have
been made under the programme:
Number of shares Average purchase Transaction
Accumulated, last 435,000 162,272,753
08 February 2010 90,000 373.8999 33,650,991
09 February 2010 90,000 374.0000 33,660,000
10 February 2010 90,000 374.0290 33,662,610
11 February 2010 90,000 378.7490 34,087,410
12 February 2010 90,000 385.0110 34,650,990
Accumulated under the 885,000 331,984,754
Transactions related to Novo Nordisk's incentive programmes have resulted in a
net sale by Novo Nordisk of 359,222 B shares in the period from 8 February 2010
to 12 February 2010. The shares in these transactions were not part of the Safe
Harbour repurchase programme.
With the transactions stated above, Novo Nordisk owns a total of 31,281,948
treasury shares, corresponding to 5.0% of the share capital. The total amount of
shares in the company is 620,000,000 including treasury shares.
Novo Nordisk is a healthcare company and a world leader in diabetes care. In
addition, Novo Nordisk has a leading position within areas such as haemostasis
management, growth hormone therapy and hormone replacement therapy. Novo Nordisk
manufactures and markets pharmaceutical products and services that make a
significant difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs more than 29,300 employees in 76
countries, and markets its products in 179 countries. Novo Nordisk's B shares
are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed
on the New York Stock Exchange under the symbol 'NVO'. For more information,
Elin K Hansen Klaus Bülow Davidsen
Tel: (+45) 4442 3450 Tel: (+45) 4442 3176
Kasper Roseeuw Poulsen
Tel: (+45) 4442 4471
In North America: In North America:
Sean Clements Hans Rommer
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
Company Announcement no 9 / 2010
Company Announcement no 9 2010:
elNacho : Cheuvreux belässt Novo Nordisk auf 'Underperform'
© 2010 APA-dpa-AFX-Analyser
elNacho : Credit Suisse hebt Novo Nordisk auf 470 Kronen
© 2010 APA-dpa-AFX-Analyser
elNacho : Berenberg Bank belässt Novo Nordisk auf 'Hold'
elNacho : Quartalsbericht
Danish drug maker Novo Nordisk A/S said Tuesday its first quarter profit soared 23 percent, helped by increased sales of its core insulin products.
The world's top producer of insulin said net profit in the January to March period reached 3.3 billion kroner ($595 million), up from 2.7 billion kroner in the same period in 2009.
Sales increased by 9 percent to 13.7 billion kroner ($2.45 billion) from 12.5 billion kroner.
"We are encouraged by the solid business performance in the first quarter of 2010. The increasing use of our modern insulins is the primary driver of growth," Chief Executive Lars Rebien Soerensen said.
Rebien Soerensen added the launch of new diabetes drug Victoza in Europe was "progressing well" in the United States and Europe.
License fees and other operating income were 224 million kroner ($40.15 million), up from 87 million kroner in the first three months of 2009. The development is primarily driven by income from Novo Nordisk's portfolio of intellectual property including a non-recurring income of approximately 100 million kroner related to a settlement, the group said.
Novo Nordisk upgraded its forecast for operating profit growth in 2010 to "more than 10 percent," from an earlier forecast of "around 10 percent."
The company's shares rose 2.10 percent to 455 kroner ($81.55) in morning trading in Copenhagen.
Headquartered in Copenhagen, Novo Nordisk employs 29,000 people in 76 countries.
On the net:
elNacho : Novo Nordisk Named Best Place to Work
(Logo: http://www.newscom.com/cgi-bin/prnh/20020404/NVOLOGO )
"It is an honor for Novo Nordisk to be named the #1 Best Place to Work in New Jersey four of the last six years," said Jeff Frazier, vice president of human resources. "The sustained level of employee engagement that enables us to maintain such a high ranking is indicative of our employees' commitment to our triple bottom line, as well as the company's mission to change diabetes and help people living with the diseases we treat."
The ranking is based on an independent assessment of policies, practices and demographics as well as a comprehensive employee survey.
In the survey, employees expressed a high level of satisfaction with their work environment. Nearly all of those surveyed had positive responses to the statements, "I would recommend my company's products/services to a friend," "I am willing to give extra effort to help my company succeed," and "I can trust what this organization tells me."
Novo Nordisk's recognition can be attributed in part to unique programs like College Coach, which helps parents navigate how to finance their children's college education. A recently launched program called "I am Novo Nordisk" affirms employees' positive responses to such programs. In "I am Novo Nordisk," employees who exemplify the company's values share their stories about why they love working for the company.
The "Best Place to Work in New Jersey" award is part of the weekly publication's annual survey to honor the companies in New Jersey that show a dedication to their employees' growth and quality of life, which was published in a supplement to the April 26 issue and online at http://www.njbiz.com/.
About Novo Nordisk
Novo Nordisk is a global healthcare company with more than 87 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to social responsibility to employees and customers, environmental soundness and economic success. Headquartered in Denmark, Novo Nordisk employs more than 29,300 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchange in Copenhagen and its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk-us.com.
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, firstname.lastname@example.org
Novo Nordisk Inc.
CONTACT: Sean Clements of Novo Nordisk Inc., +1-609-514-8400 begin_of_the_skype_highlighting +1-609-514-8400 end_of_the_skype_highlighting begin_of_the_skype_highlighting +1-609-514-8400 end_of_the_skype_highlighting,
Web Site: http://novonordisk-us.com/